"Somatostatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.
| Descriptor ID |
D013004
|
| MeSH Number(s) |
D06.472.699.327.700.875 D06.472.699.587.780 D12.644.400.400.700.875 D12.644.548.365.700.875 D12.644.548.586.780 D12.776.631.650.405.700.875
|
| Concept/Terms |
Somatostatin- Somatostatin
- SRIH-14
- Somatotropin Release-Inhibiting Factor
- Somatotropin Release Inhibiting Factor
- Cyclic Somatostatin
- Somatostatin-14
- Somatostatin 14
- Somatotropin Release-Inhibiting Hormone
- Somatotropin Release Inhibiting Hormone
- Somatostatin, Cyclic
|
Below are MeSH descriptors whose meaning is more general than "Somatostatin".
Below are MeSH descriptors whose meaning is more specific than "Somatostatin".
This graph shows the total number of publications written about "Somatostatin" by people in this website by year, and whether "Somatostatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Somatostatin" by people in Profiles.
-
Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data. Neurosurg Rev. 2022 Oct; 45(5):3067-3081.
-
Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol. 2012 Mar; 13(1):24-34.
-
Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics. Oncologist. 2012; 17(2):220-32.
-
Investigation of cancer cell lines for peptide receptor-targeted drug development. J Drug Target. 2011 Sep; 19(8):719-30.
-
Application of human pancreatic carcinoid BON cells for receptor-targeted drug development. J Drug Target. 2011 Sep; 19(8):666-74.
-
Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008 May; 57(5):1349-54.
-
Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care. 2005 May; 28(5):1124-31.
-
Somatostatin-induced gastric protection against ethanol: involvement of nitric oxide and effects on gastric mucosal blood flow. Regul Pept. 2003 Jan 31; 110(2):107-13.
-
Effects of calcitonin gene-related peptide on somatostatin and gastrin gene expression in rat antrum. Regul Pept. 1998 Feb 02; 73(2):75-82.
-
Calcitonin gene-related peptide modulates acid-mediated regulation of somatostatin and gastrin release from rat antrum. Gastroenterology. 1995 Sep; 109(3):701-6.